Table 3.
Results of univariate and multivariate cox regression models for OS.
| Factor | Hazard ratio (95% confidence interval) | p-value |
|---|---|---|
| Univariate | ||
| Age | 1.04 (1.01, 1.07) | 0.008 |
| CA19-9 at diagnosis | 1.00003 (0.99999, 1.00006) | 0.145 |
| Pre-SBRT CA19-9 | 1.00022 (1.00007, 1.00036) | 0.004 |
| Post-SBRT CA19-9 | 1.0004 (1.0002, 1.0006) | <0.001 |
| Change in CA19-9 | 1.00007 (0.99972, 1.00043) | 0.687 |
| CA19-9 normalization | 0.35 (0.12, 0.98) | 0.045 |
| Previous EBRT Dose | 0.03 (0.00, infinity) | 0.998 |
| Recurrent lesion vs. non-recurrent | 0.51 (0.30, 0.89) | 0.017 |
| GTV volume (cm3) | 1.004 (0.995, 1.013) | 0.390 |
| PTV volume (cm3) | 1.01 (1.00, 1.03) | 0.044 |
| BED ≥ 60 | 0.77 (0.45, 1.30) | 0.3268 |
| Multiple fractions vs. single fraction | 0.72 (0.51, 1.02) | 0.068 |
| Chemo: Gemcitibine + Capcitabine vs. Gemcitibine | 0.92 (0.54, 1.55) | 0.746 |
| Chemo: FU based vs. Gemcitibine | 0.51 (0.18, 1.44) | 0.203 |
| Stage | 1.90 (1.52–2.37) | <0.001 |
| Surgery vs. no surgery | 0.30 (0.20, 0.45) | <0.001 |
| Dose | 0.97 (0.94, 1.00) | 0.040 |
| Multivariate analysis | ||
| Surgery | 0.36 (0.19, 0.70) | 0.002 |
| CA19-9 Normalization | 0.32 (0.1, 0.94) | 0.037 |
| Post-SBRT CA19-9 | 1.0004 (1.0001, 1.0005) | 0.003 |